Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients

Table 2 Univariate survival analysis of clinicopathologic variables in 241 patients n (%)

Variable	n(%)	5-year overall survival rate (%)	P value
All	241	52.80
Sex			0.740
Female	116 (48.1)	50.40
Male	125 (51.9)	54.30
Age (yr)			0.000
1 ( ≤50)	14 (5.8)	78.60
2 (51-60)	18 (7.5)	32.00
3 (61-70)	78 (32.3)	57.50
4 (71-80)	87 (36.1)	57.30
5 (> 80)	44 (18.3)	35.20
Site			0.006
S	40 (16.6)	33.30
M	50 (20.7)	70.80
I	150 (62.2)	51.50
Surgery			0.400
Total gastrectomy	191 (79.3)	53.10
Subtotal gastrectomy	50 (20.7)	52.60
Lauren			0.500
Intestinal	150 (62.2)	56.50
Diffuse	58 (24.0)	48.50
Mixed	15 (6.2)	33.90
T stage (6th edition)			< 0.0001
T1	64 (26.6)	86.20
T2	135 (56.0)	45.40
T3	37 (15.3)	23.30
T4	5 (2.1)	0.00
T stage (7th edition)			< 0.0001
T1	64 (26.6)	86.20
T2	33 (13.7)	71.00
T3	102 (42.3)	37.30
T4	42 (17.4)	20.50
N stage (6th edition)			< 0.0001
N0	81 (33.6)	77.30
N1	73 (30.3)	55.70
N2	50 (20.7)	27.60
N3	37 (15.4)	22.90
N stage (7th edition)			< 0.0001
N0	81 (33.6)	77.30
N1	39 (16.2)	67.50
N2	35 (14.5)	43.00
N3	86 (35.7)	25.90
Stage (6th edition)			< 0.0001
I	87 (36.1)	76.40
II	59 (24.5)	61.50
III	55 (22.8)	24.40
IV	40 (16.6)	21.20
Stage (7th edition)			< 0.0001
I	70 (29)	85.60
II	56 (23.3)	61.50
III	115 (47.7)	27.00
Lymph node ratio			< 0.0001
I (0)	81 (33.6)	77.30
II (0.01-0.09)	41 (17.1)	65.40
III (0.1-0.25)	50 (20.7)	44.50
IV (> 0.25)	69 (28.6)	21.00

S: Superior; M: Middle; I: Inferior.